首页 Arbutus生物制药(usABUS)-基本信息

Arbutus生物制药(usABUS)-基本信息

日报更新时间:

周报更新时间:04-11 03:39

行情信息

今开价:3.2

最高价:3.2

成交量:1982945.0

昨收价:3.2

最低价:3.02

最新价:3.07

行情图标
概要信息

中文名称:Arbutus生物制药


英文名称:Arbutus Biopharma


简介:Arbutus Biopharma Corporation提供的一系列治疗产品包括其内部研发的产品


电话:1-604-4193200


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 持股信息
  • 领导人信息

Arbutus Biopharma Corporation主要利用RNAi技术来治疗疾病。公司产品包括: TKM-HBV——理由RNA干扰技术治疗乙肝,目前处于I期临床试验阶段; OCB-030——治疗乙肝的亲环蛋白抑制剂候选产品; CYT-003——(治疗乙肝)TLR9激动剂; (治疗乙肝)衣壳装配抑制剂,用于口服; (治疗乙肝)表面抗原分泌抑制剂;  STING激动剂——(治疗乙肝)干扰素基因刺激研究计划; cccDNA形成抑制剂——(治疗乙肝)用于减少受感染的肝细胞的cccDNA的量; cccDNA表观遗传修饰——(治疗乙肝)抑制新病毒和cccDNA的亚病毒颗粒的形成; TKM-PLK1——一个肿瘤学产品平台,用于胃肠神经内分泌肿瘤、肾上腺皮质癌和肝癌治疗,目前处于I/II临床试验阶段; TKM-Ebola——抗埃博拉病毒治疗的I期临床试验; TKM-Ebola-Guinea——RNA干扰技术治疗埃博拉病毒,目前处于II期临床试验阶段; TKM-Marburg——治疗马尔堡感染; TKM-HTG——一种多组分的RNAi治疗技术,用于靶向定位肝脏当中甘油三酯代谢过程中的一系列基因组合; TKM-ALDH——一种醛脱氢酶,用于治疗严重的酒精使用障碍(酒精过敏); 此外,Arbutus Biopharma Corporation与其他公司合作开发的产品包括:ALN-TTR02(靶向治疗运甲状腺素蛋白淀粉样变性)、ALN-VSP(用于治疗肝癌)、ALN-PCS02(治疗高胆固醇血症)、Marqibo(治疗费城染色体阴性急性淋巴细胞性白血病)、DCR-PH1(治疗I型原发性高草酸尿症)。

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Bailard Inc 228000 0.39% 12000 5.56% 2019-03-31
Morgan Stanley - Brokerage Accounts 965931 1.66% -119644 -11.02% 2019-03-31
BMO Asset Management Inc 979124 1.69% 12017 1.24% 2019-03-31
Bank of Montreal 979124 1.69% 11520 1.19% 2019-03-31
Ladenburg Thalmann FI Services Inc 1765415 3.04% -- -- 2019-03-31
EcoR1 Capital, LLC 2172883 3.75% -1108619 -33.78% 2019-03-31
BlackRock Inc 2312132 3.99% -112550 -4.64% 2019-03-31
PRIMECAP Management Company 4040900 6.97% -- -- 2019-03-31
RTW INVESTMENTS, LLC 5510223 9.50% 1174477 27.09% 2019-03-31
Foresite Capital Management IV, LLC 804446 1.39% -777829 -49.16% 2019-03-31
BlackRock Fund Advisors 668649 1.18% -1030599 -60.65% 2019-07-31
Hudson Bay Capital Management LP 650000 1.12% -- -- 2019-03-31
Dafna Capital Management LLC 246900 0.43% -- -- 2019-03-31
Geode Capital Management, LLC 262990 0.45% -208874 -44.27% 2019-03-31
Fidelity Management & Research Company 270450 0.48% 72285 36.48% 2019-07-31
Vanguard Group Inc 282626 0.49% -3110 -1.09% 2019-03-31
Northern Trust Corp 313760 0.54% 2642 0.85% 2019-03-31
Northern Trust Investments N A 313760 0.54% 2642 0.85% 2019-03-31
Northern Trust Investments Inc 556722 0.98% -5618 -1.00% 2019-07-31
State Street Corporation 574476 0.99% -23456 -3.92% 2019-03-31
Goldman Sachs Group Inc 220650 0.38% 133253 152.47% 2019-03-31
State Street Global Advisors 286900 0.49% -- -- 2019-06-30
BlackRock Asset Management Canada Ltd 705174 1.22% -1188 -0.17% 2019-05-31
Advanced Series Trust 278000 0.48% -- -- 2019-05-31
Vanguard 189666 0.33% -- -- 2019-03-31
EAM Investors, LLC 342949 0.62% 342949 -- 2018-09-30
T. Rowe Price Associates, Inc. 497328 0.90% 497328 -- 2018-09-30
Jennison Associates LLC 269699 0.49% 269699 -- 2018-09-30
Bank of New York Mellon Corp 191857 0.35% 108398 129.88% 2018-09-30
AXA Investment Managers UK Ltd 542547 0.98% -- -- 2018-11-30
BlackRock Institutional Trust Company NA 350721 0.63% 345353 6433.55% 2018-06-30
D. E. Shaw & Co LP 470508 0.85% -239954 -33.77% 2018-06-30
Morgan Stanley & Co Inc 733329 1.32% 221906 43.39% 2018-06-30
Ladenburg Thalmann Asset Management Inc 1765315 3.18% -- -- 2018-06-30
Goldman, Sachs & Co. 353338 0.64% 246668 231.24% 2018-06-30
AXA SA 535644 0.97% -5490 -1.01% 2018-03-31
AllianceBernstein L.P. 535644 0.97% -5490 -1.01% 2018-03-31
Dexxon Holdings Inc. 16013540 -- -- -- 2017-10-16
Viking Global Investors LP 16013540 -- -- -- 2018-01-12
SVF GP (Jersey) Ltd. 16013540 -- -- -- 2018-01-12
Qvt Financial LP 16013540 -- -- -- 2018-01-12
Roivant Sciences Ltd 16013540 -- 1164000 7.84% 2018-04-11
State Street Corp 499079 -- 485319 3527.03% 2018-06-30
Renaissance Technologies Corp 250652 -- 7152 2.94% 2018-06-30
J.P. Morgan Securities Inc 210331 -- -11998 -5.40% 2018-06-30
Baker Bros Advisors LP 180582 -- -- -- 2018-06-30
Saint Olive Gestion 120000 -- -- -- 2018-07-31
AllianceBernstein LP 535644 -- -5490 -1.01% 2018-03-31
Oxford Asset Management, LLC 253746 -- -88007 -25.75% 2018-03-31
Northern Trust Asset Management 85896 -- 82 0.10% 2018-07-31
Teachers Advisors Inc 145963 -- 145963 -- 2018-06-30
Ascend Capital LLC 290720 -- 290720 -- 2018-03-31
Victory Capital Management Inc. 167150 -- 16430 10.90% 2018-03-31
K2 PRINCIPAL FUND LP 151078 -- -110248 -42.19% 2018-03-31
Deutsche Bank AG 163451 -- 94113 135.73% 2017-12-31
Point72 Asset Management, L.P. 224655 -- 224655 -- 2017-09-30
Credit Suisse First Boston (CSFB) 176091 -- 91 0.05% 2017-09-30
Telemetry Investments, L.L.C. 218400 -- -6600 -2.93% 2017-06-30
Sabby Management LLC 248600 -- -399600 -61.65% 2017-06-30
Sphera Funds Management Ltd. 300000 -- -- -- 2016-09-30
Suffolk Capital Management LLC 314993 -- -126922 -28.72% 2016-09-30
Millennium Management LLC 476122 -- -109954 -18.76% 2016-09-30
Armistice Capital, LLC 1400000 -- 992000 243.14% 2016-09-30
Healthcor Management LP 2000000 -- -258300 -11.44% 2016-09-30
Falcon Edge Capital LP 2618000 -- -- -- 2016-09-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
BSO Bio Sant¨? 120000 0.21% -- -- 2019-07-31
PrimeCap Odyssey Aggressive Growth Fund 4040900 7.11% -- -- 2019-06-30
iShares Nasdaq Biotechnology ETF 573388 1.01% 38651 7.23% 2019-07-30
Vanguard Explorer Fund 188366 0.33% -- -- 2019-03-31
NT R2000 Index Fund - NL 134126 0.24% 4749 3.67% 2019-06-30
London Life Smaller Company (M) 28500 0.05% -- -- 2019-07-31
Northern Trust Russell 2000 Index DC NL 101824 0.18% 2524 2.54% 2019-06-30
NT R2000 Value Index Fund - Non-Lending 100666 0.18% -- -- 2019-06-30
iShares Micro-Cap ETF 95261 0.17% -- -- 2019-07-30
NT R2000 Value Index Fund - Lending 72967 0.13% 6806 10.29% 2019-06-30
DekaLux-BioTech 28500 0.05% -- -- 2019-03-31
NT R2000 Growth Index Fund - Lending 28528 0.05% 511 1.82% 2019-06-30
NT R2000 Growth Index Fund - Non-Lending 40303 0.07% -- -- 2019-06-30
Fidelity 40830 0.07% -20133 -33.02% 2019-05-31
SPDR 43069 0.08% -- -- 2019-07-31
NT R2000 Index Fund - Lending 50288 0.09% 8147 19.33% 2019-06-30
EQ/2000 Managed Volatility Portfolio 52878 0.09% -- -- 2019-05-31
State Street Russell Small Cap 141600 0.25% -- -- 2019-06-30
VALIC Company II Small Cap Value Fund 68448 0.12% -25752 -27.34% 2019-05-31
TIAA-CREF Small-Cap Blend 52216 0.09% -- -- 2019-05-31
CREF Stock Account 45136 0.08% -- -- 2019-05-31
AST Small Cap Value 208200 0.36% -69800 -25.11% 2019-05-31
iShares Russell 2000 Small-Cap Index Fd 46173 0.08% 4799 11.60% 2019-05-31
State Street Russell Small/Mid Cap 140200 0.24% -- -- 2019-05-31
Schwab Small Cap Index Fund 73368 0.13% -- -- 2019-05-31
NVIT Multi-Manager Small Cap Value Fund 97412 0.17% -33188 -25.41% 2019-05-31
Russell 2000 Index Non-Lendable Fund E 69787 0.12% 904 1.31% 2019-03-31
iShares Russell 2000 Value ETF 263059 0.45% -159 -0.06% 2019-06-27
iShares Russell 2000 ETF 713754 1.23% 1584 0.22% 2019-06-27
iShares Russell 2000 Growth ETF 79246 0.14% -87 -0.11% 2019-06-27
iShares US Small Cap ETF (CAD-Hedged) 705174 1.22% -1188 -0.17% 2019-05-30
ALPS Medical Breakthroughs ETF 132835 0.23% -- -- 2019-05-31
Candriam Eqs L Biotechnology 105000 0.18% -- -- 2019-03-31
AXA 2000 Managed Volatility Portfolio 52878 0.09% -- -- 2019-01-31
Vanguard Russell 2000 Index Fund 41614 0.07% -636 -1.51% 2019-01-31
Master Small Cap Index Series 41374 0.07% -- -- 2019-01-31
AQR Small Cap Momentum Style Fund 39727 0.07% -- -- 2018-12-31
LVIP SSgA Small Cap Index Fund 38900 0.07% -- -- 2019-01-31
Victory RS Science and Technology Fund 72510 0.13% -- -- 2018-09-30
Invesco FTSE RAFI US 1500 Small-Mid ETF 132665 0.24% 21808 19.67% 2018-03-18
PGIM Jennison Health Sciences Fund 156557 0.28% -- -- 2018-11-30
Bayview US Bio Venture MF 90800 0.16% 90800 -- 2018-02-09
OMI IM GBP AXA Framlington Biotech 542547 0.98% -- -- 2018-05-31
Dreyfus Select Managers Small Cap Gr Fd 101111 0.18% -10620 -9.50% 2018-09-30
SEI Small Cap II (SIIT) Fund 52714 0.10% -- -- 2018-09-30
CS (Lux) Global Biotech Innovators Eq 88000 0.16% -- -- 2017-10-31
Multi-Manager Small Cap Equity Strat Fd 103966 0.19% -- -- 2018-09-30
iShares Russell 2000 Growth 116894 0.22% -113 -0.10% 2018-09-12
BlackRock Russell 2000 49279 0.09% 49279 -- 2018-06-30
PNC Multi Factor Small Cap Value I 32717 0.06% -281 -0.85% 2018-07-31
SEI Small Cap Growth A (SIMT) 42000 0.08% -- -- 2018-08-31
Vanguard Russell 2000 ETF 39759 0.07% 742 1.90% 2018-07-31
iShares Nasdaq Biotechnology 629227 1.19% -1197 -0.19% 2018-09-12
iShares Russell 2000 Value 244361 0.46% -- -- 2018-09-12
Dreyfus Select Managers Small Cap Gr A 111731 0.20% 111731 -- 2018-07-31
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 85896 0.16% 82 0.10% 2018-07-31
iShares Micro-Cap 94285 0.18% -- -- 2018-09-12
Active Port 80942 0.15% 80942 -- 2018-07-31
Schwab Small Cap Index 65900 0.12% -- -- 2018-07-31
SEI Small Cap A (SIMT) 79000 0.14% -- -- 2018-08-31
Prudential Jennison Health Sciences A 57989 0.10% 57989 -- 2018-07-31
AXA 2000 Managed Volatility K 52878 0.10% -- -- 2018-07-31
CREF Stock R1 51708 0.09% -2798 -5.13% 2018-07-31
RS Technology A 72510 0.13% -- -- 2018-06-30
SEI Small Cap II A (SIIT) 52714 0.10% -6725 -11.31% 2018-08-31
TIAA-CREF Small-Cap Blend Idx Inst 43079 0.08% -- -- 2018-07-31
PRIMECAP Odyssey Aggressive Growth 4000400 7.23% -- -- 2018-06-30
BlackRock Russell 2500 48073 0.09% 48073 -- 2018-06-30
Master Small Cap Index 25797 0.05% -- -- 2018-07-31
SEI Small Cap A (SIIT) 25668 0.05% 25668 -- 2018-07-31
LVIP SSgA Small Cap Index Std 38900 0.07% 38900 -- 2018-06-30
ProShares Ultra Nasdaq Biotechnology 19215 0.03% -2090 -9.81% 2018-07-31
Northern Small Cap Index 20762 0.04% 20762 -- 2018-06-30
iShares Russell 3000 12445 0.02% -- -- 2018-08-02
BNY Mellon EB DL Small Cap SIF 24353 0.04% 24353 -- 2018-06-30
AQR Small Cap Momentum Style I 19222 0.03% 19222 -- 2018-06-30
The Vanguard Russell 2000 Value Index 17813 0.03% 17813 -- 2018-06-30
The Vanguard Russell 2000 Growth Index 16783 0.03% 16783 -- 2018-06-30
State Street Small/Mid Cap Equity Index 4300 0.01% 4300 -- 2018-06-30
BlackRock Russell 3000 12543 0.02% 12543 -- 2018-06-30
Pacific Select Small-Cap Index I 13917 0.03% 13917 -- 2018-06-30
ProShares Ultra Russell2000 3127 0.01% 3127 -- 2018-06-30
ProShares UltraPro Nasdaq Biotechnology 1879 -- -292 -13.45% 2018-06-30
ProShares UltraPro Russell2000 1685 -- 1685 -- 2018-06-30
PowerShares Russell 2000 Equal Wt ETF 1284 -- -- -- 2018-07-04
Vanguard Growth & Income Inv 1300 -- -300 -18.75% 2018-03-31
GE Investments Total Return 1 768 -- 768 -- 2018-06-30
PowerShares Zacks Micro Cap ETF 11192 0.03% 2240 25.02% 2018-06-28
PowerShares FTSE RAFI US 1500 Sm-Mid ETF 110481 0.20% -- -- 2018-03-08
Vanguard Health Care ETF 228 -- -- -- 2018-01-31
Ohio National Bryton Growth 314993 0.57% -126922 -28.72% 2016-09-30
Franklin Biotechnology Discovery Fund 803000 1.50% -- -- 2015-09-30
BB Adamant Global Biotech 125000 0.20% -- -- 2015-07-31
BSO Bio Santé 110000 0.20% -- -- 2015-10-31
FPIL Invesco Global Health Care 92197 0.20% -- -- 2015-06-30
CS (Lux) Biotechnology Equity Fund 88000 0.20% -- -- 2015-09-30
RS Small Cap Growth Equity VIP Series 37930 0.10% 7320 23.90% 2015-06-30
FCP OP MEDICAL BioHealthTrends 36450 0.10% -- -- 2015-09-30
BioShares Biotechnology Clncl Trls Fd 23026 -- -- -- 2015-11-19
Franklin Biotechnology Discovery 1253300 2.30% -- -- 2015-07-31

Herbert J. Conrad Herbert J. Conrad is a businessperson who founded Reliant Pharmaceuticals LLC and who has been at the head of 7 different companies. Presently, he is Chairman for Matinas BioPharma Holdings, Inc. Mr. Conrad is also on the board of Arbutus Biopharma Corp. and Celldex Therapeutics, Inc. In his past career Mr. Conrad occupied the position of Chairman of Bone Care International, Inc., Chairman of Pharmasset, Inc., Chairman of GenVec, Inc., Chairman at Sapphire Therapeutics, Inc., Chairman of Matinas BioPharma, Inc., President & Director at Roche Pharmaceuticals, Inc., Director at Reliant Pharmaceuticals LLC and President-Pharmaceuticals Division at F. Hoffmann-La Roche Ltd. Herbert J. Conrad received an undergraduate degree and a graduate degree from Arnold & Marie Schwartz College of Pharmacy & Health Science.
Frank L. Karbe Presently, Frank L. Karbe is Chief Financial & Accounting Officer for Myovant Sciences Ltd. and Chief Financial & Accounting Officer of Myovant Sciences, Inc. He is also on the board of Arbutus Biopharma Corp. In his past career he occupied the position of President of The Color Run LLC, Chief Financial Officer & Executive Vice President at Exelixis, Inc. and Vice President-Healthcare Group at Goldman Sachs & Co. LLC. He received an MBA from WHU-Otto Beisheim School of Management.
Vivek Ramaswamy Founder of Roivant Sciences GmbH and Campus Venture Network, Inc., Vivek Ramaswamy is a businessperson who has been at the head of 8 different companies and currently occupies the position of Chairman for Arbutus Biopharma Corp. and President & Chief Executive Officer at Roivant Sciences GmbH, President & Chief Executive Officer at Roivant Sciences, Inc. (a subsidiary of Roivant Sciences GmbH). He is also on the board of Roivant Sciences Ltd. and Myovant Sciences Ltd. (former Chairman). In the past Mr. Ramaswamy was President for Campus Venture Network, Inc., Investment Analyst at QVT Financial LP, Director at Axovant Sciences Ltd., Chairman at Arbutus Biopharma, Inc. and Chief Executive Officer for Axovant Sciences, Inc. He received a graduate degree from Yale Law School and an undergraduate degree from Harvard College.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐